Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy - PubMed (original) (raw)
Review
Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy
Samson T Jacob et al. Cancer Gene Ther. 2005 Aug.
Abstract
Promoter methylation-mediated silencing is a hallmark of many established tumor suppressor genes. This review focuses on the methylation and suppression of a receptor-type tyrosine phosphatase gene, PTPRO, in a variety of solid and liquid tumors. In addition, PTPRO exhibits many other characteristics of a bona fide tumor suppressor. Reactivation of genes silenced by methylation using inhibitors of DNA methyltransferases and histone deacetylases, and the potential application of PTPRO as a molecular target for cancer therapy have been discussed.
Figures
Figure 1
Protein isoforms of PTPRO. The full-length and truncated forms of PTPRO differ mainly with respect to their extracellular domains (fibronectin type III repeats). Each of these forms gives rise to two isoforms that are products of alternatively spliced transcripts, that is, by splicing of E17.
Figure 2
Schematic representation of the PTPRO gene.
References
- Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16:6–21. - PubMed
- Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–428. - PubMed
- Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143–153. - PubMed
- Wade PA, Gegonne A, Jones PL, et al. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet. 1999;23:62–66. - PubMed
- Wade PA, Jones PL, Vermaak D, et al. A multiple subunit Mi-2 histone deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase. Curr Biol. 1998;8:843–846. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA086978/CA/NCI NIH HHS/United States
- R01 CA086978-01A2/CA/NCI NIH HHS/United States
- ES 10874/ES/NIEHS NIH HHS/United States
- R01 CA081024-01A2/CA/NCI NIH HHS/United States
- CA 86978/CA/NCI NIH HHS/United States
- R01 ES010874/ES/NIEHS NIH HHS/United States
- R01 CA081024/CA/NCI NIH HHS/United States
- CA 81024/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical